AbbVie Company Profile (NYSE:ABBV)

About AbbVie

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company operates in pharmaceutical products segment. Its products are focused on treating conditions, such as chronic autoimmune diseases, in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, as well as other serious health conditions. AbbVie also has a pipeline of new medicines, including over 50 compounds or indications, such as immunology, virology/liver disease, oncology, neurological diseases and women's health. Its product portfolio includes HUMIRA, IMBRUVICA, HCV products, additional virology products, metabolics/hormones products, endocrinology products and other products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: ABBV
  • CUSIP: 00287Y10
Key Metrics:
  • Previous Close: $61.48
  • 50 Day Moving Average: $61.69
  • 200 Day Moving Average: $62.54
  • 52-Week Range: $1,625,098,000.00 - $52.73
  • Trailing P/E Ratio: 17.02
  • Foreward P/E Ratio: 9.59
  • P/E Growth: 0.78
  • Market Cap: $100.38B
  • Outstanding Shares: 1,625,098,000
  • Beta: 1.57
  • Net Margins: 23.22%
  • Return on Equity: 141.55%
  • Return on Assets: 12.64%
  • Debt-to-Equity Ratio: 5.76%
  • Current Ratio: 1.79%
  • Quick Ratio: 1.61%
Additional Links:
Companies Related to AbbVie:

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (?)
Ratings Breakdown: 1 Sell Rating, 9 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.27)
Consensus Price Target: $70.20 (13.65% upside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetDetails
2/14/2017Jefferies Group LLCReiterated RatingBuy$90.00View Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00View Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00View Rating Details
11/8/2016Leerink SwannReiterated RatingHoldView Rating Details
11/8/2016BMO Capital MarketsReiterated RatingMarket Perform$63.00View Rating Details
10/31/2016Credit Suisse GroupDowngradeOutperform -> Neutral$70.00 -> $60.00View Rating Details
9/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$78.00View Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00View Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00View Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00View Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00View Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00View Rating Details
6/7/2016Deutsche Bank AGReiterated RatingHoldView Rating Details
6/6/2016Cowen and CompanyDowngradeOutperform -> Market Perform$77.00 -> $70.00View Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$47.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00View Rating Details
7/24/2015Evercore ISIReiterated RatingBuy$70.00View Rating Details
7/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$85.00View Rating Details
6/17/2015Piper Jaffray CompaniesInitiated CoverageOverweightView Rating Details
(Data available from 2/19/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.20$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.49 EPS
Next Year EPS Consensus Estimate: $6.44 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Annual Dividend:$2.56
Dividend Yield:4.14%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:70.52% (Based on Trailing 12 Months of Earnings)
46.63% (Based on Current Year Consensus EPS Estimate)
39.75% (Based on Next Year Consensus EPS Estimate)
Track Record:44 Years of Consecutive Dividend Growth

Dividend History for AbbVie (NYSE:ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.11%
Institutional Ownership Percentage: 66.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for AbbVie (NYSE:ABBV)
News IconAbbVie Inc.'s (ABBV) Stock price of $61.48 — Traders Focused Stock (NYSE:ABBV) - February 18 at 9:24 AM
News IconINVESTING IN MARIJUANA STOCKS 💰 8 Pot Stocks to Watch in 2017! (NYSE:ABBV) - February 17 at 6:50 PM logoAbbVie (ABBV) Increases Buyback by $5B (NYSE:ABBV) - February 17 at 6:49 PM logo8:00 am AbbVie authorizes a $5 bln increase to AbbVie's existing stock repurchase program (NYSE:ABBV) - February 17 at 6:49 PM logoAbbVie Announces $5 Billion Increase to Stock Repurchase Program (NYSE:ABBV) - February 17 at 6:49 PM logoABBVIE INC. Files SEC form 10-K, Annual Report (NYSE:ABBV) - February 17 at 6:49 PM
News IconShares of AbbVie Inc. (ABBV) Sees Large Inflow of Net Money Flow (NYSE:ABBV) - February 16 at 8:19 PM
News IconShares of AbbVie Inc. (ABBV) Sees Large Inflow of Net Money Flow (NYSE:ABBV) - February 16 at 8:19 PM
News IconThe Top Three Holders Of AbbVie Inc. (ABBV) (NYSE:ABBV) - February 16 at 8:19 PM
News IconThe Top Three Holders Of AbbVie Inc. (ABBV) (NYSE:ABBV) - February 16 at 8:19 PM logoWhy I Just Bought AbbVie Stock (NYSE:ABBV) - February 16 at 8:19 PM logoAbbVie Declares Quarterly Dividend (NYSE:ABBV) - February 16 at 8:19 PM
News IconSell-Side Analyst's Predictions: AbbVie Inc. (ABBV), Wal-Mart Stores, Inc. (WMT) - The USA Commerce (NYSE:ABBV) - February 16 at 3:18 PM logoUK's National Institute For Health And Care Excellence Rejects ... - Market Exclusive (NYSE:ABBV) - February 16 at 3:18 PM logoNICE Rejects AbbVie’s Leukemia Drug Venclexta (NYSE:ABBV) - February 16 at 3:18 PM
News IconUK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) (NYSE:ABBV) - February 16 at 2:25 PM logoAbbVie declares $0.64 dividend (NYSE:ABBV) - February 16 at 2:04 PM
News IconToday's Brokerage Rating: The Williams Companies, Inc. (WMB), AbbVie Inc. (ABBV) - StockNewsJournal (NYSE:ABBV) - February 16 at 5:58 AM logoAbbVie: Strong Dividend, Strong Buy - Seeking Alpha (NYSE:ABBV) - February 16 at 5:58 AM logoAbbVie to Present at the Cowen and Company 37th Annual Health Care Conference (NYSE:ABBV) - February 16 at 5:58 AM logoEli Lilly Is Great Stock to Buy Now (NYSE:ABBV) - February 16 at 5:58 AM
News IconAverage Brokerage Rating Of AbbVie Inc. (ABBV), BB&T Corporation (BBT) - The USA Commerce (NYSE:ABBV) - February 15 at 1:24 AM
News IconTaking a Fresh Look at AbbVie Inc. (ABBV) - StockNewsJournal (NYSE:ABBV) - February 14 at 3:22 PM
News IconAbbVie Inc. (ABBV) stock moves up, “Buy” rating reiterated by Jefferies Group LLC Analysts - The Ledger Gazette (NYSE:ABBV) - February 14 at 3:22 PM
News IconThe Technical Case for and Against AbbVie Inc. (ABBV) - The USA Commerce (NYSE:ABBV) - February 13 at 3:20 PM
News IconShares of AbbVie Inc. (ABBV) Sees Large Inflow of Net Money Flow - Highland Mirror (NYSE:ABBV) - February 13 at 3:20 PM
News IconTraders Secrets on Corning Incorporated (GLW), AbbVie Inc. (ABBV) - StockNewsJournal (NYSE:ABBV) - February 13 at 3:20 PM logoSentiment in AbbVie is lower than in its peers which is what I look for in solid dividend stocks. - Seeking Alpha (NYSE:ABBV) - February 13 at 3:20 PM
News IconJust the Facts on AbbVie Inc. (ABBV) - StockNewsJournal (NYSE:ABBV) - February 10 at 3:17 PM logoBetter Buy: AbbVie Inc. vs. Eli Lilly - Motley Fool (NYSE:ABBV) - February 10 at 3:17 PM logoAre Short Sellers Doubting Trump by Hiking Bets in Major Pharma? (NYSE:ABBV) - February 10 at 3:17 PM logoBetter Buy: AbbVie Inc. vs. Eli Lilly (NYSE:ABBV) - February 10 at 8:55 AM
News IconBuy or Sell? Average Brokerage Ratings on Schlumberger Limited (SLB), AbbVie Inc. (ABBV) - StockNewsJournal (NYSE:ABBV) - February 9 at 3:14 PM
News IconTdam Usa Cuts Position in AbbVie Inc (ABBV) by $28787014 - Highland Mirror (NYSE:ABBV) - February 9 at 3:14 PM
News IconAnalyst Perspectives: AbbVie Inc (NYSE:ABBV) - Post Registrar (NYSE:ABBV) - February 9 at 1:22 AM
News IconAbbVie Inc. (NYSE:ABBV)- Profitability Analysis To Overcome Risk: Achaogen, Inc. (NASDAQ:AKAO) - Street Wise Report (press release) (blog) (NYSE:ABBV) - February 8 at 8:20 PM logoIs AbbVie Inc (NYSE:ABBV) a Good Investment Without the Humira Factor? - Library For Smart Investors (NYSE:ABBV) - February 8 at 8:20 PM logoFinding the Best Value Investment in Healthcare (NYSE:ABBV) - February 8 at 8:20 PM logoTop Reasons To Buy AbbVie In 2017 - Part 1 - Seeking Alpha (NYSE:ABBV) - February 8 at 3:19 PM logoTop Reasons To Buy AbbVie In 2017: Part 2 - Seeking Alpha (NYSE:ABBV) - February 8 at 3:19 PM logoThe Zacks Analyst Blog Highlights: Apple, Visa and AbbVie (NYSE:ABBV) - February 8 at 3:19 PM
News IconAbbVie Inc. (ABBV) Consensus Earnings Predictions (NYSE:ABBV) - February 8 at 1:23 AM
News IconThe Ameriprise Financial Inc. Sells 43304 Shares of AbbVie Inc. (ABBV) (NYSE:ABBV) - February 8 at 1:23 AM
News IconAviance Capital Management LLC Buys 181876 Shares of AbbVie Inc. (ABBV) (NYSE:ABBV) - February 8 at 1:23 AM
News IconDrug Manufacturers – Major: AbbVie Inc. (NYSE:ABBV) Position of the day (NYSE:ABBV) - February 8 at 1:23 AM logoEarnings No Longer a Headwind for Stocks (NYSE:ABBV) - February 8 at 1:23 AM
News IconWhat Analysts Report Shows About AbbVie Inc. (NYSE:ABBV)? - Transcript Daily (NYSE:ABBV) - February 7 at 8:22 PM logoStocks on Trader's Radar: AbbVie Inc. (ABBV), eBay Inc. (EBAY), Corning Incorporated (GLW) - iStreetWire (NYSE:ABBV) - February 7 at 3:17 PM
News IconTechnicals in Focus for AbbVie Inc. (ABBV) - The USA Commerce (NYSE:ABBV) - February 7 at 3:17 PM
News IconStocks in Concern on New Development: AbbVie Inc. (NYSE:ABBV), Alcobra Ltd. (NASDAQ:ADHD) - Street Wise Report (press release) (blog) (NYSE:ABBV) - February 7 at 3:17 PM


What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, February 17th. Investors of record on Thursday, April 13th will be paid a dividend of $0.64 per share on Monday, May 15th. This represents a $2.56 annualized dividend and a dividend yield of 4.14%. The ex-dividend date of this dividend is Tuesday, April 11th.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

15 brokerages have issued twelve-month target prices for AbbVie's stock. Their forecasts range from $47.00 to $90.00. On average, they anticipate AbbVie's share price to reach $70.20 in the next twelve months.

When will AbbVie announce their earnings?

AbbVie is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
  • According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. However, Viekira is facing intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to market. Amgen’s biosimilar version of Humira received FDA approval in Sep 2016. Abbvie could see some of its dominant share in the arthritis market contract when Amgen’s new drug is launched." (9/28/2016)

  • Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

Who owns AbbVie stock?

AbbVie's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.39%), Federated Investors Inc. PA (0.93%), Glenview Capital Management LLC (0.56%), Janus Capital Management LLC (0.53%), Prudential PLC (0.43%) and FMR LLC (0.38%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Thomas A Hurwich, Timothy J Richmond and William J Chase.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, FMR LLC, Highfields Capital Management LP, Renaissance Technologies LLC, Orbimed Advisors LLC, Loomis Sayles & Co. L P, Franklin Resources Inc. and Nicholas Co. Inc. WI. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Thomas A Hurwich, Timothy J Richmond and William J Chase.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, State Street Corp, Asset Management One Co. Ltd., Prudential PLC, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main, Russell Investments Group Ltd., Raymond James Financial Services Advisors Inc. and Baird Financial Group Inc..

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AbbVie stock cost?

One share of AbbVie stock can currently be purchased for approximately $61.77.

AbbVie (NYSE:ABBV) Chart for Sunday, February, 19, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Earnings History Chart

Earnings by Quarter for AbbVie (NYSE:ABBV)

Dividend History Chart

Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Last Updated on 2/19/2017 by Staff